Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey S Chamberlain

Showing results (11-20 of 166) with videos related to

Pageof 17
Sort By:
Expert Opinion on Biological Therapy|July 26, 2003
Gene therapy for muscular dystrophy - a review of promising progressPaul Gregorevic, Jeffrey S Chamberlain
Current Opinion in Neurology|August 12, 2015
Viral vector-mediated gene therapiesKatrin Hollinger, Jeffrey S Chamberlain
Nature Communications|August 31, 2018
Cas9 immunity creates challenges for CRISPR gene editing therapiesJulie M Crudele, Jeffrey S Chamberlain
Birth Defects Research. Part C, Embryo Today : Reviews|January 21, 2006
Relevance of motoneuron specification and programmed cell death in embryos to therapy of ALSGlen B Banks, Jeffrey S Chamberlain
Nature Medicine|February 6, 2010
Muscling in: Gene therapies for muscular dystrophy target RNAJoel R Chamberlain, Jeffrey S Chamberlain
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2003
Gutted adenoviral vectors for gene transfer to muscleJeannine M Scott, Jeffrey S Chamberlain
Expert Reviews in Molecular Medicine|June 27, 2009
Emerging strategies for cell and gene therapy of the muscular dystrophiesLindsey A Muir, Jeffrey S Chamberlain
Human Molecular Genetics|June 26, 2019
AAV-based gene therapies for the muscular dystrophiesJulie M Crudele, Jeffrey S Chamberlain
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 19, 2017
Progress toward Gene Therapy for Duchenne Muscular DystrophyJoel R Chamberlain, Jeffrey S Chamberlain
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 27, 2008
Recombinant adeno-associated virus transduction and integrationBrian R Schultz, Jeffrey S Chamberlain
Pageof 17

Showing results (11-20 of 166) with videos related to

Sort By:
Pageof 17
Expert Opinion on Biological Therapy|July 26, 2003
Gene therapy for muscular dystrophy - a review of promising progressPaul Gregorevic, Jeffrey S Chamberlain
Current Opinion in Neurology|August 12, 2015
Viral vector-mediated gene therapiesKatrin Hollinger, Jeffrey S Chamberlain
Nature Communications|August 31, 2018
Cas9 immunity creates challenges for CRISPR gene editing therapiesJulie M Crudele, Jeffrey S Chamberlain
Birth Defects Research. Part C, Embryo Today : Reviews|January 21, 2006
Relevance of motoneuron specification and programmed cell death in embryos to therapy of ALSGlen B Banks, Jeffrey S Chamberlain
Nature Medicine|February 6, 2010
Muscling in: Gene therapies for muscular dystrophy target RNAJoel R Chamberlain, Jeffrey S Chamberlain
Methods in Molecular Biology (Clifton, N.J.)|February 25, 2003
Gutted adenoviral vectors for gene transfer to muscleJeannine M Scott, Jeffrey S Chamberlain
Expert Reviews in Molecular Medicine|June 27, 2009
Emerging strategies for cell and gene therapy of the muscular dystrophiesLindsey A Muir, Jeffrey S Chamberlain
Human Molecular Genetics|June 26, 2019
AAV-based gene therapies for the muscular dystrophiesJulie M Crudele, Jeffrey S Chamberlain
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 19, 2017
Progress toward Gene Therapy for Duchenne Muscular DystrophyJoel R Chamberlain, Jeffrey S Chamberlain
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 27, 2008
Recombinant adeno-associated virus transduction and integrationBrian R Schultz, Jeffrey S Chamberlain
Pageof 17